ライフサイエンスコーパス: esophageal carcinoma

1 ecimens (seven Barrett's metaplasias and six esophageal carcinomas).

2 r, in development of Barrett's esophagus and esophageal carcinoma.

3 ) for intramucosal (T1a) or submucosal (T1b) esophageal carcinoma.

4 atients undergoing nonoperative treatment of esophageal carcinoma.

5 ificantly improved survival in patients with esophageal carcinoma.

6 ging and impacts on therapy of patients with esophageal carcinoma.

7 ion does not alter the TNM classification of esophageal carcinoma.

8 nd p53 mutations in patients with late-stage esophageal carcinoma.

9 of 171 patients identified, 2 had died from esophageal carcinoma.

10 and confers treatment resistance in lung and esophageal carcinomas.

11 eal cancer-derived cell lines and in primary esophageal carcinomas.

12 ions were examined in two main histotypes of esophageal carcinomas.

13 tissue tumors (20%), osteosarcomas (16%) and esophageal carcinomas (13%).

14 4 Barrett's esophagus (BA) metaplasias and 8 esophageal carcinomas (3 squamous cell carcinomas and 5

15 Oral-esophageal carcinomas, a model system to investigate mol

16 ceptor (EGFR) is frequently overexpressed in esophageal carcinoma and its precursor lesions.

17 tecan had significant activity in metastatic esophageal carcinoma and resulted in significant relief

18 nd EUS FNA for preoperative nodal staging of esophageal carcinoma and to measure the impact of each s

19 ate that 15-LOX-1 is down-regulated in human esophageal carcinomas and that NSAIDs induce apoptosis i

20 s an important new agent in the treatment of esophageal carcinoma, and further evaluation of this age

21 rative chemoradiation, long-term outcomes of esophageal carcinoma are best predicted utilizing histol

22 ithelium, including lung, head and neck, and esophageal carcinomas, are the leading causes of cancer-

23 of a 5.4 cM region at 7q31-q35 in 43 primary esophageal carcinomas, as well as mutational analyses of

24 at: (a) 15-LOX-1 was down-regulated in human esophageal carcinomas; (b) NSAIDs induced 15-LOX-1 expre

25 rigin or progression of at least a subset of esophageal carcinomas, but that ST7 is not the target ge

26 However, in six of nine esophageal carcinoma cell lines, no FHIT RT-PCR product

27 Squamous carcinoma of the head and neck and esophageal carcinoma demonstrate avid (18)F-FDG uptake.

28 one for patients with potentially resectable esophageal carcinoma did not demonstrate a statistically

29 Patients with esophageal carcinoma (EC) who are treated with definitiv

30 Esophageal carcinoma has a special place in gastrointest

31 Patients with localized esophageal carcinoma have a 5-year survival rate of less

32 Esophageal carcinomas have high fatality rates, making c

33 s for the treatment of partially obstructive esophageal carcinoma, high-grade dysplasia associated wi

34 leading to its overexpression in breast and esophageal carcinomas; however, the contribution of stab

35 11, patients with a resectable intrathoracic esophageal carcinoma, including the gastroesophageal jun

36 Therapy of esophageal carcinoma is stage dependent.

37 , the prognosis for patients with inoperable esophageal carcinoma is still poor and the reliability o

38 tt's esophagus with high-grade dysplasia, or esophageal carcinoma limited to the lamina propria.

39 cinomas and dysplasias, gastric cancers, and esophageal carcinomas, manifest microsatellite instabili

40 ), gastric cancer (n = 2), and squamous-cell esophageal carcinoma (n = 1) were retrieved.

41 e development or progression of most primary esophageal carcinomas or UCANs, although lack of express

42 Among esophageal carcinomas RAR-beta mRNA was expressed in 62%

43 Although this is not yet the case for esophageal carcinoma, recent improved chemoradiation reg

44 ave sequenced exon 5 of cyclin D1 in primary esophageal carcinoma samples and in cell lines derived f

45 cember 1999 to March 2001, all patients with esophageal carcinoma seen at the Mayo Clinic Rochester w

46 gnosed with stage pT3-4Nx-0M0 or pT1-4N1-3M0 esophageal carcinoma (squamous cell or adenocarcinoma) f

47 ican Joint Committee on Cancer, 7th Edition, esophageal carcinoma staging system is derived from pati

48 In esophageal carcinomas that overexpress cyclin D1, Fbx4 i

49 schizophrenia and one for the MMP-2 gene and esophageal carcinoma, to evaluate the performance of the

50 cancer, including liver metastasectomy, and esophageal carcinoma treated primarily with chemoradiati

51 y of 43 patients with potentially resectable esophageal carcinoma treated with an intensive regimen o

52 ot for LRC in patients with locally advanced esophageal carcinoma treated with definitive radiochemot

53 A total of 125 patients with esophageal carcinoma were enrolled.

54 One hundred patients with esophageal carcinoma were randomized to receive either s

55 nd multifocal neoplasia in patients with pT1 esophageal carcinoma who underwent esophagectomy without

56 substantial antitumor activity in metastatic esophageal carcinoma, with a remarkable complete respons